High density lipoprotein mimicking nanoparticles for atherosclerosis

Jun Chen1, Xixi Zhang1, Reid Millican1

  • 1Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA.

Nano Convergence
|January 28, 2020
PubMed

Insights

High-density lipoproteins (HDL) mimic nanoparticles offer promising therapeutic strategies for atherosclerosis, a leading cause of global mortality. This review highlights recent advancements in HDL-mimicking nanoparticles for imaging, targeting, and treating atherosclerosis.

Area of Science:

  • Biomedical Engineering
  • Cardiovascular Research
  • Nanotechnology

Background:

  • Atherosclerosis is a primary cause of global mortality, contributing to myocardial infarction, ischemic stroke, and peripheral arterial disease.
  • High-density lipoproteins (HDL), or "good cholesterol", exhibit anti-atherosclerotic properties by facilitating cholesterol removal from plaque foam cells.

Purpose of the Study:

  • To review recent progress in the development of HDL-mimicking nanoparticles (NPs).
  • To summarize the applications of these HDL-mimicking NPs in imaging, targeting, and treating atherosclerosis.

Main Methods:

  • Literature review of recent advancements in HDL-mimicking nanoparticle design.
  • Analysis of studies focusing on the application of these nanoparticles in atherosclerosis.

Main Results:

  • Significant progress has been made in designing functional HDL-mimicking NPs.
  • These NPs show potential for various applications in atherosclerosis management.

Conclusions:

  • HDL-mimicking NPs represent a promising therapeutic avenue for atherosclerosis.
  • Further development and application of these NPs are crucial for combating cardiovascular disease.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
279
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
692
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K